# Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934

> **NCT01975818** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 201 (actual)

## Conditions studied

- Anemia
- Renal Insufficiency, Chronic

## Interventions

- **DRUG:** Molidustat (BAY 85-3934)
- **BIOLOGICAL:** Epoetin alfa/beta

## Key facts

- **NCT ID:** NCT01975818
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-28
- **Primary completion:** 2015-10-23
- **Final completion:** 2015-12-15
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2019-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01975818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01975818, "Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01975818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*